Surrozen Reports Q2 2026 Financial Results with $50.2M Net Income and Increased Revenue

Surrozen, Inc. reported its financial results for the second quarter of 2026, revealing a significant increase in revenue and a net income of $50.2 million, compared to a net income of $39.7 million in the same period last year. The company generated $5.0 million in collaboration and license revenue during the quarter, attributed to milestone achievements under its collaboration agreement with Boehringer Ingelheim. This marks a substantial increase from the $983,000 in revenue reported in the second quarter of 2025. However, for the first half of 2026, Surrozen recorded a net loss of $77.3 million, a stark contrast to the net income of $12.8 million reported for the same period in 2025.

Operating expenses for the second quarter of 2026 totaled $15.4 million, a 54% increase from $10.0 million in the prior year, driven primarily by higher research and development costs, which rose by 40% to $8.5 million. General and administrative expenses also saw a significant increase of 74%, totaling $6.9 million. The company’s accumulated deficit as of June 30, 2026, stood at approximately $604.6 million, with cash and cash equivalents amounting to $102.0 million, reflecting a cash burn of $19.9 million for the first half of the year.

Strategically, Surrozen has focused on advancing its product candidates targeting the Wnt pathway, particularly in ophthalmology. The company is preparing to submit an Investigational New Drug (IND) application for its lead candidate, SZN-8141, by the end of the third quarter of 2026, with plans to initiate a Phase 1b/2a clinical trial called DUET by year-end 2026. Additionally, Surrozen has entered into a new sales agreement to issue and sell up to $50 million of shares of common stock, following the termination of its previous At-the-Market (ATM) program.

Operationally, Surrozen has made significant strides in its collaboration with Boehringer Ingelheim, which has resulted in multiple milestone payments. The company recognized $10 million in collaboration revenue for the first half of 2026, reflecting the successful achievement of development milestones. However, the company also faces challenges, including the need for substantial additional funding to support ongoing clinical trials and research activities. Surrozen anticipates that it will continue to incur significant losses as it advances its product candidates through clinical development and regulatory submissions.

Looking ahead, Surrozen's management believes that its existing cash and cash equivalents will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the potential need for additional capital to support its long-term business plan, particularly if cash burn exceeds current projections. The ongoing development of its product candidates and the ability to secure necessary funding will be critical to the company's future success and ability to achieve profitability.